{"id":"placebo-auto-injector","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Nocebo effects (symptom reporting attributable to expectation rather than active drug)"}]},"_chembl":{"chemblId":"CHEMBL5095440","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo auto-injectors are pharmaceutical delivery devices designed to mimic the appearance, administration route, and user experience of active drug auto-injectors without containing therapeutic agents. They are used in blinded clinical trials to control for injection-related effects, device handling, and psychological factors, allowing researchers to isolate the true pharmacological effects of investigational drugs.","oneSentence":"A placebo auto-injector device delivers no active pharmaceutical ingredient, serving as a control or inert comparator in clinical studies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:31.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control/comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT07220473","phase":"PHASE2","title":"Tirzepatide to Slow Biological Aging","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-02-27","conditions":"Aging, LONGEVITY 1","enrollment":90},{"nctId":"NCT07083154","phase":"PHASE3","title":"GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-09-27","conditions":"Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes","enrollment":420},{"nctId":"NCT07135141","phase":"NA","title":"Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-09-30","conditions":"Severe Obesity","enrollment":256},{"nctId":"NCT06738719","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-01-03","conditions":"Moderately to Severely Active Rheumatoid Arthritis","enrollment":192},{"nctId":"NCT04943068","phase":"PHASE3","title":"A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)","status":"COMPLETED","sponsor":"Kwang Dong Pharmaceutical co., ltd.","startDate":"2021-05-10","conditions":"Hypoactive Sexual Desire Disorder","enrollment":193},{"nctId":"NCT05621070","phase":"PHASE3","title":"Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-03","conditions":"Primary Hypercholesterolaemia and Mixed Dyslipidemia","enrollment":582},{"nctId":"NCT06449625","phase":"PHASE2","title":"Semaglutide in Auto-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Klaus Gottlob Müller","startDate":"2024-08-12","conditions":"Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity","enrollment":40},{"nctId":"NCT05780905","phase":"PHASE4","title":"Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-01-11","conditions":"Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack","enrollment":50},{"nctId":"NCT03433755","phase":"PHASE3","title":"Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-05-09","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":259},{"nctId":"NCT04848402","phase":"PHASE1","title":"A Device Study in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-09-27","conditions":"Healthy","enrollment":60},{"nctId":"NCT04121780","phase":"PHASE2","title":"Growth Hormone Replacement Therapy for Retried Professional Football Players","status":"RECRUITING","sponsor":"Center for Neurological Studies","startDate":"2019-10-08","conditions":"TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury","enrollment":42},{"nctId":"NCT03931161","phase":"PHASE4","title":"Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)","status":"UNKNOWN","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2019-09-04","conditions":"Carotid Artery Stenosis","enrollment":33},{"nctId":"NCT04510844","phase":"PHASE4","title":"Evolocumab In Advanced Chronic Kidney Disease Trial","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2021-03-01","conditions":"Chronic Kidney Diseases, High Cholesterol","enrollment":""},{"nctId":"NCT03067844","phase":"PHASE3","title":"Vascular Effects of Alirocumab in Acute MI-Patients","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-04-25","conditions":"Coronary Vessel, Coronary Circulation, Atheroma; Myocardial","enrollment":294},{"nctId":"NCT03589885","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-19","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT02333071","phase":"PHASE3","title":"1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2014-12","conditions":"Hypoactive Sexual Desire Disorder","enrollment":723},{"nctId":"NCT02338960","phase":"PHASE3","title":"2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2015-01","conditions":"Hypoactive Sexual Desire Disorder","enrollment":714},{"nctId":"NCT03287609","phase":"PHASE3","title":"EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-23","conditions":"Acute Coronary Syndrome","enrollment":308},{"nctId":"NCT02683746","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":308},{"nctId":"NCT01663402","phase":"PHASE3","title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":18924},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT03811223","phase":"PHASE4","title":"Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2019-08","conditions":"Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III","enrollment":30},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02289963","phase":"PHASE3","title":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":199},{"nctId":"NCT01926782","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":803},{"nctId":"NCT00712673","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Diabetes Mellitus, Type 2","enrollment":680},{"nctId":"NCT00763451","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus, Type 2","enrollment":484},{"nctId":"NCT00713830","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 2","enrollment":859},{"nctId":"NCT00688701","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 2","enrollment":361},{"nctId":"NCT00715624","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 2","enrollment":496},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT02660736","phase":"PHASE1","title":"Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01169779","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT00866658","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-03","conditions":"Diabetes Mellitus, Type 2","enrollment":311},{"nctId":"NCT00976937","phase":"PHASE3","title":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":319},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01617655","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-06","conditions":"Hypercholesterolaemia","enrollment":107},{"nctId":"NCT00319501","phase":"PHASE3","title":"Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Seizures, Epilepsies, Partial, Epilepsy, Complex Partial","enrollment":234},{"nctId":"NCT01623115","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":486},{"nctId":"NCT01644175","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":316},{"nctId":"NCT00643526","phase":"EARLY_PHASE1","title":"A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2007-12","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Placebo Auto-Injector","genericName":"Placebo Auto-Injector","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"A placebo auto-injector device delivers no active pharmaceutical ingredient, serving as a control or inert comparator in clinical studies. Used for Clinical trial control/comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}